Valentino license
This article was originally published in The Rose Sheet
Executive Summary
Procter & Gamble Prestige Beauté, the beauty division's fine fragrance unit, signed a licensing agreement with Italian fashion designer Valentino to market fragrance and beauty products under the designer name effective Aug. 1, company announces July 30. Valentino license has global growth potential, P&G says, noting agreement is in line with corporate strategy to "develop faster-growing, higher margin, more asset efficient businesses with global leadership potential." Valentino brand has feminine, glamorous heritage that will complement P&G's existing fine fragrance portfolio, firm says. Lineup, which currently includes Hugo Boss, Jean Patou and Lacoste, also will be expanded with addition of Wella fragrance brands. Valentino fragrances previously were marketed by Unilever Prestige...
You may also be interested in...
P&G/Clarins deal
Clarins Fragrance Group will distribute fragrances under the Valentino label in the U.S. under deal with Procter & Gamble, effective immediately, firms announce. Clarins, which distributes P&G's Jean Patou and Lacoste fragrances in specialty stores, department stores and boutiques, maintains it is well suited to distribute the specialty-door Valentino brand. P&G's Prestige Beaute division recently signed a licensing agreement with the Italian designer Valentino to market the brand's fragrances and beauty products (1"The Rose Sheet" Aug. 4, 2003, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.